Accepted for Publication: July 29, 2020.
Corresponding Author: Samantha Frank, MD, Division of Otolaryngology−Head and Neck Surgery, Department of Surgery, University of Connecticut School of Medicine, 263 Farmington Ave, Farmington, CT 06030 (email@example.com).
Published Online: September 17, 2020. doi:10.1001/jamaoto.2020.3053
Author Contributions: Drs Frank, Capriotti, and Tessema had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: All authors.
Acquisition, analysis, or interpretation of data: Frank, Capriotti, Westover, Tessema.
Drafting of the manuscript: Frank, Capriotti, Pelletier, Tessema.
Critical revision of the manuscript for important intellectual content: Frank, Brown, Capriotti, Westover, Tessema.
Statistical analysis: Capriotti, Westover.
Obtained funding: Capriotti.
Administrative, technical, or material support: Brown, Capriotti, Westover, Tessema.
Supervision: Brown, Capriotti, Westover, Pelletier, Tessema.
Conflict of Interest Disclosures: Dr Brown reported personal financial investment in Halodine outside the submitted work. Dr Capriotti is the executive director of Veloce BioPharma and reported a patent to multiple related drugs issued and licensed by Veloce BioPharma. Dr Pelletier is a consultant for Veloce BioPharma and reported equity in both Veloce BioPharma and Halodine. Dr Tessema reported personal financial investment in Halodine outside the submitted work, and has a patent to multiple drug products pending. No other disclosures were reported.
Funding/Support: The funding for the laboratory materials used in this study was supplied by Veloce BioPharma.
Role of the Funder/Sponsor: Veloce BioPharma had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. However, the individual authors listed who are related to Veloce BioPharma did assist with design of the study and review of the manuscript.
K , Schechtman
S , Hogikyan
ND , Teoh
AYB , McGrath
B , Brenner
MJ . COVID-19 pandemic: what every otolaryngologist–head and neck surgeon needs to know for safe airway management. Otolaryngol Head Neck Surg
. 2020;162(6):804-808. doi:10.1177/0194599820919751PubMedGoogle ScholarCrossref
AD , Welling
DB , Carter
et al. Endonasal instrumentation and aerosolization risk in the era of COVID-19: simulation, literature review, and proposed mitigation strategies. Int Forum Allergy Rhinol
. 2020;10(7):798-805. doi:10.1002/alr.22577PubMedGoogle ScholarCrossref
B , Frank
S , Bidra
A . SARS-CoV-2 viral inactivation using low dose povidone-iodine oral rinse—immediate application for the prosthodontic practice. J Prosthodont
. 2020. doi:10.1111/jopr.13207PubMedGoogle Scholar
LJ , Kubik
MW , Baddour
K , Snyderman
CH , Rowan
NR . Consideration of povidone-iodine as a public health intervention for COVID-19: utilization as “personal protective equipment” for frontline providers exposed in high-risk head and neck and skull base oncology care. Oral Oncol
. 2020;105:104724. doi:10.1016/j.oraloncology.2020.104724PubMedGoogle Scholar
M , Koburger-Janssen
T , Eickmann
M , Zorn
J . In vitro bactericidal and virucidal efficacy of povidone-iodine gargle/mouthwash against respiratory and oral tract pathogens. Infect Dis Ther
. 2018;7(2):249-259. doi:10.1007/s40121-018-0200-7PubMedGoogle ScholarCrossref
AS , Pelletier
JS , Westover
JB , Frank
S , Brown
SM , Tessema
B . Rapid in-vitro inactivation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using povidone-iodine oral antiseptic rinse. J Prosthodont
. 2020;29(6):529-533. doi:10.1111/jopr.13209PubMedGoogle Scholar
S , Capriotti
J , Brown
SM , Tessema
B . Povidone-iodine use in sinonasal and oral cavities: a review of safety in the COVID-19 era. Ear Nose Throat J
. Published online June 10, 2020.PubMedGoogle Scholar
R , Payandeh
J , Al-Salman
et al. The efficacy of diluted topical povidone-iodine rinses in the management of recalcitrant chronic rhinosinusitis: a prospective cohort study. Eur Arch Otorhinolaryngol
. 2019;276(12):3373-3381. doi:10.1007/s00405-019-05628-wPubMedGoogle ScholarCrossref
W , Panchmatia
R , Samoy
K , Habib
A , Thamboo
A , Al-Salman
et al Topical povidone-iodine as an adjunctive treatment for recalcitrant chronic rhinosinusitis. Eur J Rhinol Allergy
2019;2(2):45-50. doi:10.5152/ejra.2019.166Google ScholarCrossref
MA , Farrales
MS , Loya
RM , Pura
MA , Uy
H . The effect of 1% povidone iodine as a pre-procedural mouthrinse in 20 patients with varying degrees of oral hygiene. J Philipp Dent Assoc
. 1996;48(2):31-38.PubMedGoogle Scholar
Jr . The relationship between autoimmune thyroid disease and iodine intake: a review. Endokrynol Pol
. 1992;43(suppl 1):53-69.PubMedGoogle Scholar